MedTrace Logo

Pergolide Treatment and Valvular Heart Disease

NCT00234364 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2007-09-20

No results posted yet for this study

Summary

In a blinded echocardiographic study we investigate the frequency of valvular abnormalities in a group of Parkinson patients treated with either ergot derived dopamine agonists (pergolide and cabergoline) or non-ergot derived dopamine agonists (pramipexole and ropinirole). The ability to detect patients with valvular abnormalities by clinical approach is examined.

Conditions

Sponsors & Collaborators

  • Århus Amt

    lead OTHER_GOV

Principal Investigators

  • Vibeke G Rasmussen, MD · Aarhus University Hospital Skejby

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2007-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00234364 on ClinicalTrials.gov